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ABSTRACT 31 
 32 
Objectives: The study objective was to investigate the prevalence and clinical characteristics of 33 
phenobarbitone-associated adverse effects in epileptic cats.  34 
 35 
Methods: The medical records of two veterinary referral clinics from 2007 to 2017 were searched for cats 36 
fulfilling the inclusion criteria of a diagnosis with epilepsy, treatment with phenobarbitone, and available 37 
follow-up information on the occurrence of adverse effects. Follow-up information was obtained from 38 
the medical records of the primary veterinarian and referral institutions and a questionnaire completed 39 
by the cats’ owners. 40 
 41 
Results: Seventy-seven cats met the inclusion criteria. 58 were affected by idiopathic epilepsy and 19 by 42 
structural epilepsy. One or more of the following adverse effects were reported in 47% of the cats: 43 
sedation (89%), ataxia (53%), polyphagia (22%), polydipsia (6%), polyuria (6%) and anorexia (6%). Logistic 44 
regression analyses revealed significant associations between adverse effect occurrence and both 45 
phenobarbitone starting dosage and administration of a second anti-epileptic drug. For each 1mg/kg BID 46 
increment of phenobarbitone, the likelihood of adverse effects increased 3.1 times. When a second anti-47 
epileptic drug was used, the likelihood of adverse effects increased 3.2 times. No association was 48 
identified between epilepsy aetiology and adverse effect occurrence. An idiosyncratic adverse effect, 49 
characterised by severe neutropenia and granulocytic hypoplasia, was diagnosed in one cat. This resolved 50 
following phenobarbitone discontinuation. 51 
 52 
Conclusions and relevance: The prevalence of phenobarbitone-associated adverse effects was 47%. 53 
Sedation and ataxia were most common. These are type A adverse effects and are predictable from 54 
phenobarbitone’s known pharmacologic properties. In the majority of cases, adverse effects occurred 55 
within the first month of treatment and were transient. Idiosyncratic (type B) adverse effects, that are not 56 
anticipated given the known properties of the drug, occurred in one cat (1.3% of the study population). 57 
Increased phenobarbitone starting dosage and the addition of a second anti-epileptic drug were 58 
significantly associated with the occurrence of adverse effects.  59 
 60 
INTRODUCTION 61 
 62 
Phenobarbitone (PB) is considered the most effective first line antiepileptic drug (AED) used in epileptic 63 
cats(1). However, the evidence for PB’s efficacy and safety profile in the feline veterinary literature is 64 
weak(1). Drug-related adverse effects (AEs) are categorised as type A or type B (also known, respectively, 65 
as type I and II AEs).  66 
 67 
Type A AEs are those that can be explained by the known pharmacological properties of the agent and 68 
are therefore usually dose-dependent and predictable. Type A AEs that may affect individuals receiving 69 
PB can be understood by consideration the drug’s mechanism of action. PB exerts its anti-epileptic effect 70 
by several different means. It is an agonist of the gamma-aminobutyric acid (GABA) A receptor and also 71 
modulates this receptor to increase GABA’s affinity for it(2). This causes post-synaptic chloride channels 72 
to remain open for longer, allowing greater chloride influx into, and hyperpolarisation of, the post-73 
synaptic neuron. Other purported mechanisms of action of PB include inhibition of the excitatory capacity 74 
of glutamate(3), inhibition of voltage-gated calcium channels and binding of chloride channels(4). The 75 
upshot is an increase in seizure threshold and a decrease in the spread of excitation to surrounding 76 
neurons(5). While this provides efficacious seizure control, the overall effect of barbiturate administration 77 
is depression of the central nervous system. It can therefore be anticipated that type A AEs such as 78 
sedation and ataxia will occur with PB therapy(4). Polyuria and polyphagia are also commonly reported 79 
during PB treatment; these are thought to arise through PB’s inhibition of anti-diuretic hormone 80 
release(5).Type B AEs are not dose-related, are unpredictable and are unrelated to the known mechanism 81 
of action of the drug. They can be life-threatening and often require the discontinuation of the offending 82 
agent to resolve(6,7).  83 
 84 
Sedation, ataxia, polyuria, polydipsia, and polyphagia have all been reported as type A AEs in cats treated 85 
with PB, especially during the initial two weeks of treatment(8). Accurate information on their prevalence, 86 
severity and median time to resolution is lacking(9). In dogs, some or all of these dose-related AEs can 87 
persist and significantly affect quality of life(10). It is unknown if similar phenomena occur in cats. 88 
Idiosyncratic (type B) AEs such as leukopenia, thrombocytopenia, lymphadenopathy, skin eruptions, 89 
pyrexia and coagulopathy have been described in a few feline case reports(11–15). The aim of this study 90 
was to investigate the prevalence and clinical characteristics of, and risk factors for, PB associated AEs in 91 
epileptic cats, which have not been previously evaluated in a large study population.  92 
 93 
MATERIALS AND METHODS 94 
 95 
The medical records of two referral veterinary clinics from 2007 to 2017 were retrospectively reviewed to 96 
identify cats diagnosed with epilepsy and treated with PB. Inclusion criteria were documentation of two 97 
or more unprovoked epileptic seizures (ie reactive seizures were excluded) at least 24 hours apart and 98 
availability of follow-up information on the occurrence of AEs. The following information was retrieved 99 
from the medical records of the referral institution and primary veterinarian medical records: signalment, 100 
diagnostic investigation results, epileptic seizure aetiology (structural, idiopathic) and phenotype (focal, 101 
generalized, focal developing into generalized), the occurrence of status epilepticus or cluster seizures, 102 
date of PB treatment initiation, PB dosage and serum PB levels over time, duration of PB treatment, 103 
administration of a second AED, occurrence of AEs (type and clinical features) and date of AE resolution 104 
due to achievement of steady state or following dose reduction or discontinuation of PB. In this study the 105 
2015 International Veterinary Epilepsy Task Force (IVETF) definitions for idiopathic and structural epilepsy 106 
were applied which are, respectively: ‘epilepsy in which the nature of the underlying cause is as yet 107 
unknown and with no indication of structural epilepsy’ and ‘epileptic seizures which are provoked by 108 
intracranial/cerebral pathology’.(16).  109 
 110 
The cats’ owners were invited to participate in this study by completing a questionnaire. An overview of 111 
the study and its aims were provided. The following information was requested via the questionnaire: 112 
date of questionnaire completion, PB dosage over time or reason for PB discontinuation, occurrence of 113 
any AEs (polyphagia, polydipsia/polyuria, lethargy, ataxia, pruritus, skin lesions, weight gain, changes in 114 
sleep pattern, or other AEs to be specified) and their duration following PB initiation or dosage increase, 115 
dose reduction or discontinuation of PB due to AEs and subsequent outcome, date of initiation of a second 116 
AED and associated outcome, and details of epileptic seizure frequency. When assessed at the referral 117 
institutions, all cats were examined by a board-certified neurologist or neurology resident working under 118 
supervision of a neurology diplomate. 119 
 120 
Statistical analysis: 121 
 122 
Data were analysed using XL Stat (Addinsoft SARL) and Stata (IC v 15.0, Statacorp LLC) and standard 123 
descriptive statistics were performed.  The frequency of the occurrence of AEs (total number and specified 124 
individual adverse effect) was assessed amongst cats meeting the inclusion criteria. The Mann-Witney U 125 
test was used to test for differences in PB dosage and serum concentration across cats with onset of AEs 126 
and without AEs in the first month. For the AEs occurring with the highest frequency, the influence of 127 
epilepsy aetiology (‘structural’ or ‘idiopathic’), the administration of a second AED (binary) and PB dosage 128 
(mg/kg) at the onset of adverse effects and PB serum levels (mg/L) on the likelihood of their occurrence 129 
was assessed in a mixed binomial/multinomial logistic regression model. As the PB serum levels were 130 
numerically higher by a factor of 10 than PB dose levels, and the model assesses odds per unit increase, 131 
the PB serum levels were divided by 10. Backward elimination was applied to the four variables initially 132 
modelled, with α ≤ 0.1 the inclusion criterion for retention(17).   133 
 134 
RESULTS 135 
 136 
Seventy-seven cats fulfilled the inclusion criteria. Information on sex, breed, epileptic seizure aetiology, 137 
including specific aetiology in cases of structural epilepsy, seizure phenotype, and diagnostic tests 138 
performed are detailed in table 1.  139 
 140 
Table 1: sex, breed, epileptic seizure aetiology and phenotype, and diagnostic test information of 77 cats 141 
included in the present study: 142 
 
 
Sex 
 Number Percentage 
Male entire 5 6.5 
Male neutered 36 46.8 
Female entire 2 2.6 
Female neutered 34 44.2 
 
 
Domestic short hair 55 71.4 
Domestic long hair 13 16.9 
  
Breed 
Bengal 2 2.6 
British short hair 2 2.6 
Maine Coon 1 1.3 
Tonkinese 1 1.3 
Burmese 1 1.3 
Birman 1 1.3 
Persian 1 1.3 
Epileptic seizure 
aetiology 
Idiopathic 58 75.3 
Structural 19 24.7 
Structural epilepsy 
aetiology 
Trauma 5 6.5 
Degenerative 4 5.2 
Vascular 4 5.2 
Infectious/inflammatory 3 3.9 
Anomalous 2 2.6 
Neoplastic 1 1.3 
Epileptic seizure 
phenotype 
Generalised tonic clonic 51 66.2 
Focal seizures 26 33.8 
Cluster seizures or status 
epilepticus 
36 46.8 
 
 
 
 
 
Diagnostic tests  
Haematology and serum 
biochemistry 
77 100 
Bile acid stimulation test 23 29.9 
MRI of the brain 74 96.1 
Full body CT 2 2.6 
CSF analysis 64 83.1 
FIV/FeLV test 51 66.2 
Toxoplasma gondii serology 35 45.5 
Toxoplasma gondii CSF PCR 12 15.6 
Thoracic radiographs 18 23.4 
Abdominal ultrasound 26 33.8 
Urine organic acid 
screening 
6 7.8 
 143 
 144 
Seventy-six cats underwent advanced imaging of the brain (MRI in 74 cases and whole-body CT, including 145 
the head, in 2 cases). Of the 19 cases of structural epilepsy, three cats affected by infectious or 146 
inflammatory disease received specific treatment aimed at resolving the underlying disease. The 147 
remainder received AEDs in all cases, and three cats also received anti-inflammatory doses of 148 
prednisolone.  149 
 150 
The median age of cats at the time of referral was 68.4 months (range 4 - 206.4 months; mean 71.0 ± sd 151 
46.3 months). The median age of cats affected by structural epilepsy was 73 months (range: 24 - 150 152 
months, mean: 75 months) and the median age of those affected by idiopathic epilepsy was 60 months 153 
(range: 4 -150 months, mean: 66 months).  154 
  155 
The median initial dosage of PB was 2.0 mg/kg BID (range: 0.6 - 4.4mg/kg BID; mean: 2.0 ± sd 0.71mg/kg 156 
BID). PB loading was performed in five cats; the loading dose was 3mg/kg every six hours, four times, in 157 
two patients and it was a total dose of 20mg/kg given in divided doses over 24h in the other three cats. 158 
The median duration of PB treatment was 22 months (range 1.5 - 108 months; mean 30 ± sd 27 months). 159 
36 cats (46.8%) received a concurrent AED. This was levetiracetam in 34 cases and one case each of 160 
zonisamide and imepitoin.  161 
 162 
Median follow-up time was 24 months (range 1.5 - 108 months; mean 30 ± sd 27 months). The primary 163 
veterinarians‘ medical records from the time of referral to the time of data collection were obtained for 164 
95% of cats; the remaining 5% had a re-examination in one of the referral hospitals, which provided the 165 
information required for follow-up. The owners of 36 cats (46.8%) completed the follow-up questionnaire. 166 
The owners of 69.4% of cats reported a reduction of seizure frequency of at least 50% with PB treatment. 167 
The seizure frequency was decreased by 25 - 49% in 8.3% of cats, was unchanged in 11.1% of cats and was 168 
unknown in 11.1%. 169 
 170 
Type A adverse effects: 171 
 172 
Thirty-six cats (46.7%) experienced one or more type A AEs. These are detailed in table 2.  173 
 174 
Table 2: type A adverse effects in 36 cats. Note- several cats experienced more than one adverse effect, 175 
so the percentage total is greater than 100: 176 
Adverse effect Number of affected cats Percentage 
All adverse effects 36 100 
Sedation 32 88.9 
Ataxia 19 52.8 
Polyphagia 8 22.2 
Polydipsia 2 5.6 
Polyuria 2 5.6 
Anorexia 2 5.6 
 177 
 178 
Twenty-five of these cats (69.4%) were affected by idiopathic epilepsy and 11 (30.5%) by structural 179 
epilepsy. Median PB dosage at the time of AE onset was 3 mg/kg BID (range 1.25 – 5.0mg/kg; mean 2.89 180 
± sd 0.89mg/kg) in cats who developed AEs compared to a median PB dosage of 2.0mg/kg BID (range 0.6-181 
3.5mg/kg; mean 2.09 ±sd 0.66mg/kg) during the first month of treatment in cats that did not develop AEs 182 
(Fig. 1). The difference in dosage between the two groups was statistically significant.  183 
 184 
[Insert figure 1] 185 
 186 
In cats experiencing AEs, median PB serum concentration at the time of onset of AEs was 36 mg/L (range 187 
10.3-70 mg/L; mean 35.04±sd 16.78 mg/L). In cats that did not experience AEs, median PB serum 188 
concentration at the first re-check available (range 3 weeks – 3 months after PB treatment initiation) was 189 
19.3 mg/L (range 6-40 mg/L; mean 21 ± sd 11.68 mg/L). The difference in PB serum concentration between 190 
the two groups was statistically significant. 191 
 192 
AEs were transient in 20 cats. Of these, 13 developed AEs during the inital four weeks of the PB treatment 193 
and seven developed transient AEs during ongoing PB treatment. Eight cats showed persistent AEs. It was 194 
not possible to determine the duration of the AEs in six cases and in two cases the patients were 195 
euthanased, reportedly due to the severity of the AEs.  196 
 197 
Twenty-two cats that developed AEs were administered a concurrent AED. This was levetiracetam in 21 198 
cases (dose range 15-20mg/kg; mean 29.3mg/kg; median 20mg/kg every 8 hours) and imepitoin (20mg/kg 199 
every 12 hours) in one case. One cat received the alternative AED prior to commencement of PB. In five 200 
cases the concurrent AED was started at the initiation of PB treatment, in five cases between two and four 201 
weeks following PB initiation, in nine cases more than one month after PB was initiated and the initiation 202 
time was unknown in one case. The onset of AEs was up to three weeks after the initiation of both AEDs 203 
in six cases, weeks-months before the second AED was added in eight cases, months after the second AED 204 
was added in six cats and AE onset was unknown in two cases. The respective likelihood of any adverse 205 
effect, sedation and ataxia increased by 3.2, 4.4 and 4.2 times when a second AED was used.   206 
  207 
Type B adverse effects: 208 
 209 
 One cat showed lethargy and ataxia in all limbs two months following initiation of PB treatment at 210 
2.6mg/kg BID. No epileptic seizures had occurred since starting therapy. Haematology revealed moderate 211 
leukopenia with severe neutropenia (0.0 x10^9/l ref. 2.5-12.5 x 10^9/l). Serum biochemistry was 212 
unremarkable. The serum PB level was 45mg/L. Bone marrow evaluation (cytology and core biopsy) 213 
showed severe granulocytic hypoplasia suggestive of neutrophil aplasia or immune-mediated destruction 214 
of neutrophil precursors. PB was decreased by 25% every four days and discontinued after two and half 215 
weeks; levetiracetam (20mg/kg TID) and amoxicillin/clavulanic acid (20 mg/kg BID) were commenced. Two 216 
weeks later the neutrophil count was 2.27 x 10^9/L and clinical signs had resolved. Six weeks and three 217 
months later, the neutrophil levels were 2.85 x 10^9/L and 6.40 x 10^9/L, respectively. This cat was 218 
considered to have type A adverse effects (lethargy and ataxia) as well as the type B haematological 219 
abnormalities.   220 
 221 
One cat was reported to have consistently elevated ALT two years after PB treatment initiation. Another 222 
cat was found to have generalised lymphadenopathy two months after starting PB. These cases were not 223 
classified as being affected by type B AEs as the aetiology of the clinical and biochemical abnormalities 224 
could not be definitively established from the available history.  225 
  226 
Statistical analysis: 227 
 228 
Logistic regression models were run for outcome variables ‘adverse effect’ (any type A adverse effects), 229 
‘sedation’ and ‘ataxia’. The results obtained were very similar for the three models: the initial model 230 
significantly explained the data (X2 (4) ≥ 10.6, p ≤ 0.014) with ‘administration of a second antiepileptic drug’ 231 
and ‘PB dose on the occurrence of adverse effects’ being retained in the model (p ≤ 0.011) but ‘aetiology’ 232 
and ‘PB serum level’ not making the selection criterion. The final models (X2 (2) ≥ 16.2, p < 0.0001) provided 233 
a good fit to the data (Hosmer-Lemeshaw X2 (4) ≤ 4.84, p ≥ 0.304); the retrieved odds ratios are provided 234 
in fig.2. However, for cats suffering AEs and cats not suffering AEs, PB serum concentration at the time of 235 
the onset AE (mg/L) data was not normally distributed (Shapiro-Wilk W≥ 0.904, p ≤ 0.006). A Mann-236 
Whitney U test was used to identify potential significant differences in PB serum concentration between 237 
cats suffering AEs and cats not suffering AEs. PB concentrations were significantly higher for cats suffering 238 
AEs (U = 244, p < 0.0001). PB dosage at the time of onset of AEs was significantly higher than that given 239 
during the first month of treatment to cats not affected by AEs. 240 
 241 
Figure 2: odds ratios for influence of PB dosage and administration of a second antiepileptic drug on the 242 
occurrence of adverse effects (95% CLs): 243 
Variable  
 
Any adverse effect Sedation Ataxia  
PB dosage (1mg/kg BID) 3.1 
(1.5-6.3) 
3.4 
(1.6-7.2) 
2.7 
(1.3--5.5) 
Second AED 3.2 
(1.2-9) 
4.4 
(1.5-13.0) 
4.2. 
(1.2-14.7) 
 244 
  245 
DISCUSSION 246 
 247 
This retrospective study is the first to report the prevalence and characteristics of PB-related AEs in a large 248 
population of epileptic cats. The prevalence of AEs was 47%, with sedation and ataxia being most 249 
common. These type A AEs can be expected with PB administration, given its known pharmacological 250 
properties. Increased PB starting dosage and use of a second AED were significant predictors of the 251 
occurrence of adverse effects. Serum PB concentration was significantly higher in cats suffering AEs, 252 
though logistic regression analysis determined that this could not be used as a predictor of AEs. 253 
 254 
The prevalence of sedation (41.6%), ataxia (24.7%) and polyphagia (22.2%) associated with PB 255 
administration in the present study was greater than that reported in a recent systematic review(1), which 256 
found 22%, 11% and 11% prevalence of sedation, ataxia and polyphagia, respectively. The prevalence of 257 
polydipsia (our study 3%, review 2%) was similar. Additional type A AEs which have been previously 258 
reported at a prevalence of less than 10% in cats receiving PB include paraparesis, alkaline phosphatase 259 
elevation, weight loss and behavioural change (1). These were not seen in our study population. One study 260 
of dogs treated with PB, found that sedation/lethargy, ataxia, polyuria, polydipsia and polyphagia 261 
occurred in 50%, 55%, 35%, 40% and 30% of cases, respectively(18). Therefore, type A PB-associated AEs 262 
appear to be slightly more common in dogs compared to our feline study population. 263 
 264 
In the present study, one cat receiving PB and levetiracetam showed a persistently elevated serum alanine 265 
aminotransferase level that remained elevated even after discontinuation of PB. It was not possible to 266 
determine, from the available information, the underlying aetiology of the ALT elevation, though this 267 
finding has been previously documented in cats receiving PB(1). 268 
 269 
Type B AEs that have been reported in cats receiving PB include pseudolymphoma, thrombocytopaenia, 270 
stomatitis, coagulopathy, cutaneous eruptions and hyperthermia(1,11–15). These are all rare, occurring 271 
in no more than 2% of cats treated with PB. One cat in the present study was reported to show generalised 272 
lymphadenopathy two months after starting PB; however, the aetiology of this was unknown so it was 273 
not classified as a type B AE. It could not be excluded that this cat was experiencing PB-induced 274 
pseudolymphoma but information required for further confirmation of this, such as response to 275 
treatment modification, was not available. None of the other previously reported type B AEs were seen 276 
in our study population, in which the only type B AE was granulocytic hypoplasia, occurring in one cat 277 
(1.3% of the study population). The reported prevalence of haematological abnormalities in dogs treated 278 
with PB ranges from 4.2 – 22%(7,19). These are usually subclinical(19), with only 4-5% of affected dogs 279 
showing clinical signs(7,19). Immune-mediated peripheral destruction or immune-mediated damage of 280 
precursor cells before their release into the peripheral blood are postulated mechanisms underlying PB-281 
induced haematological abnormalities in dogs and humans(6,20). The mechanism for such changes in cats 282 
has not been investigated to date.  283 
 284 
Some of the cats in the present study were reported to show PB side effects with low serum PB 285 
concentrations; five cases experienced AEs with a serum PB concentration of 10-15mg/L. One of these 286 
had post traumatic injury following a head trauma of unknown cause eight months prior to the onset of 287 
seizure activity. The remaining five had idiopathic epilepsy. The neurological deficits shown by the cat 288 
affected by trauma may have been difficult to distinguish from PB AEs. Three of these five cats received 289 
levetiracetam in addition to PB, which may explain the occurrence of AEs in these individuals despite 290 
relatively low PB serum concentration. Alternatively, it is possible that the small number of cats in this 291 
study showing AEs with a PB serum concentration <15mg/L reflects a sensitivity in these particular 292 
individuals to PB.  293 
 294 
In the present study, 22/36 cats experiencing AEs were receiving a second AED in addition to PB 295 
(levetiracetam in 21 cats, and imepitoin in one case). The addition of a second AED was significantly 296 
associated with an increased risk of AEs. It is likely that PB and the second AED have an additive effect, so 297 
increasing AEs. It is challenging to determine, in some cases, whether reported AEs should be attributed 298 
to PB, the second AED, or both. Lethargy, sedation and ataxia have been previously reported in cats 299 
treated with levetiracetam(21–23) and imepitoin(1). Adverse effects of levetiracetam and imepitoin 300 
might, therefore, might be indistinguishable from those caused by PB. However, the majority of cases in 301 
the present study treated with a second AED had AEs documented before the second AED was 302 
commenced (eight cases) or weeks to months after it was started (six cases), making a causative link 303 
impossible in the former scenario and unlikely in the latter scenario. It was impossible to determine the 304 
relative contribution of the second AED to AEs in some cases, especially when two different AEDs were 305 
commenced simultaneously. This problem has also been discussed in the human literature(6). The 306 
likelihood of AEs may be increased when two different AEDs are commenced simultaneously, as AEs were 307 
reported in all five cases in which two AEDs were started at the same time in a previously untreated cat. 308 
 309 
In the majority of cases, AEs occurring within a short time of PB treatment starting, being noticed in the 310 
first month following PB initiation in 26/36 cats. In four cases, AEs were reported a significant time after 311 
initiation of PB treatment. In two cases AEs were reported six months after starting PB, but in both these 312 
cases AEs occurred following a dose increase due to poor seizure control and inadequate serum PB 313 
concentrations. In two cases, both with idiopathic epilepsy, AEs occurred six years after starting PB. In one 314 
case this was attributed to excess serum PB concentration (38mg/L). The PB dose was reduced from 2.9 315 
to 2.1mg/kg every 12 hours and AEs resolved. Another cat developed sedation and ataxia six years 316 
following initiation of PB treatment but no further information on this case was available. Euthanasia, 317 
reportedly due to PB AEs, was a rare event, only occurring in two cases. The two cats which were 318 
euthanased both had structural epilepsy (following presumptive diagnoses of neoplasia in one case and 319 
degenerative disease in the other) and progression of these conditions may have been difficult or 320 
impossible to distinguish from AED AEs. 321 
 322 
AEs were transient in 20/36 affected cats. Broadly, the transience of PB-induced AEs can be attributed to 323 
the development of pharmacokinetic and/or pharmacodynamic tolerance(4). Pharmacokinetic tolerance 324 
occurs in dogs treated with PB whereby PB induces hepatic microsomal cytochrome P450 activity, 325 
increasing PB clearance(24). This results in reduced serum concentration over time, despite the dosage 326 
remaining unaltered. Hepatic enzyme induction does not appear to occur in the cat(25), possibly due to 327 
low levels of CYP2C(26). Pharmacodynamic tolerance is likely to account for the transience of AEs seen in 328 
the present study. Pharmacodynamic tolerance is determined by the interaction of the therapeutic 329 
molecule with receptors which can be altered over time by processes such as desensitization, receptor 330 
loss and exhaustion of mediators(27). 331 
 332 
The majority of the 19 cats affected by structural epilepsy did not receive specific treatment for their 333 
underlying disease. Only the three cats affected by inflammatory or infectious disease received specific, 334 
definitive therapy aimed at resolving the structural brain disease. The remainder of cats with structural 335 
epilepsy received AEDs and in three cases also received anti-inflammatory doses of prednisolone. Some 336 
cats with structural epilepsy may have experienced progression of disease which could affect mentation, 337 
gait and possibly appetite and thirst- signs that could be difficult to distinguish from PB AEs. 338 
 339 
Our study found that 75.3% of seizuring cats were affected by idiopathic epilepsy and 24.7% had structural 340 
epilepsy. A previous study has classified the seizure aetiology in cats as reactive, structural and idiopathic 341 
in 22%, 50% and 25% of cases respectively(28). Other studies have found the prevalence of idiopathic 342 
epilepsy to range from 30 - 60%(8,29–32). The inclusion criteria of our study, which required participating 343 
cats to have experienced 2 or more seizures at least 24 hours apart, meant that reactive cases were 344 
unlikely to be included. The ratio of idiopathic to structural aetiology was greater in our study compared 345 
to previous investigations(28,31). Possible explanations for this are: our study population may be different 346 
to that of the other studies (reflective of different geographical or genetic background), the two centres 347 
involved in our study attract a different caseload compared to other centres or that the difference is 348 
simply due to chance.  349 
 350 
While evaluating the efficacy of PB for seizure control in cats was not the primary purpose of this study, 351 
our data reveals that 69.4% of cases achieved a seizure frequency reduction of at least 50%.This parallels 352 
previous studies which have shown that the PB treatment is successful in the majority of epileptic 353 
cats(30,33). A limitation of this finding is that information on seizure frequency after treatment was only 354 
available for 31 cats. There was no obvious correlation between epilepsy aetiology and efficacy of 355 
treatment. 356 
  357 
There were several limitations in this study, some of which are inherent in retrospective investigations. 358 
Diagnostic and treatment protocols and the dosage of both PB and any concurrent AED was not 359 
standardised. Different laboratories were used to analyse blood samples and measure serum 360 
phenobarbitone concentrations. In many cases the rationale for the addition of the second AED was not 361 
available. The information and detail in medical records was variable. Only a small minority of cases (5%) 362 
had follow-up assessment by a board-certified neurologist or resident working under the supervision of a 363 
specialist. Recall bias was possible when follow-up was conducted by interviewing owners or by 364 
questionnaire. In some cases of structural epilepsy, progression of the underlying disease may have been 365 
difficult to distinguish from PB AEs. While the timing of blood sampling to test serum PB concentration 366 
with respect to PB administration varied between cases, this may not be a limitation of the study. 367 
Following administration of PB to healthy cats, the serum concentration has been shown to increase for 368 
up to two hours, then plateau for around 10 hours(34). The half-life of PB in cats has been reported to 369 
range from 43.4 to 76 hours(25,34) and in dogs is 46.3-88.7 hours(35,36). 91% of epileptic dogs have been 370 
shown to have no therapeutically relevant changes in the serum PB concentration during the 12 hour 371 
dosing interval(37) and it is possible that the situation is similar in cats, meaning that timing of sampling 372 
for PB serum concentration may not be important in the majority of cases. 373 
 374 
CONCLUSIONS 375 
 376 
The prevalence of PB-associated AEs was 47%, with sedation and ataxia being most common. These are 377 
type A AEs and tended to occur within the first month of treatment before diminishing, likely with the 378 
development of pharmacodynamic tolerance. A type B AE occurred in only one cat. Increasing PB starting 379 
dosages and the addition of a second AED were significantly associated with the occurrence of AEs.  380 
 381 
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